BioLife Solutions, Inc.
NASDAQ:BLFS · NASDAQ Capital Market
+$0.40 today
Vol 1.06M · Avg 0.52M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:BLFS · Revenue to Net Income
Key Ratios
Analysis
$99.8M of revenue converted into -$10.5M of net income for the selected period. Gross margin is 64.2% and net margin is -9.2%, showing how much revenue survives after costs and taxes. EPS is $-0.22, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $96.2M +17.0% | $82.3M +8.4% | $75.9M -0.5% | $76.2M -36.0% | $119.2M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $34.1M +19.3% | $28.6M -70.4% | $96.5M +229.1% | $29.3M -67.5% | $90.3M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $62.1M +15.7% | $53.7M +14.8% | $46.8M -0.3% | $46.9M +62.6% | $28.8M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 64.6% -0.7pp | 65.3% +3.6pp | 61.6% +0.1pp | 61.5% +37.3pp | 24.2% | 9.8% | 28.9% | 38.3% |
| Research & Development | $7.6M -4.4% | $7.9M -57.9% | $18.8M +27.0% | $14.8M +25.2% | $11.8M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $55.4M +10.4% | $50.2M -10.4% | $56.0M +24.6% | $44.9M -6.6% | $48.1M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $74.2M +22.1% | $60.8M -48.3% | $117.6M +122.5% | $52.8M -28.0% | $73.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $4.7M -45.9% | $8.7M -29.6% | $12.3M -38.4% | $20.0M +55.1% | $12.9M | $374.2M | $1.2B | $631.8M |
| EBITDA | $3.6M +135.4% | $1.5M +103.4% | -$45.2M +63.6% | -$124.2M -645.7% | -$16.7M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 3.7% +1.9pp | 1.9% +61.5pp | -59.6% +103.2pp | -162.9% -148.9pp | -14.0% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$1.1M +84.8% | -$7.1M +69.6% | -$23.4M -295.7% | -$5.9M +83.2% | -$35.2M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -1.1% +7.5pp | -8.7% +22.2pp | -30.9% -23.1pp | -7.8% +21.7pp | -29.5% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $2.7M +276.4% | $719.0K -60.3% | $1.8M +163.8% | $687.0K +41.6% | $485.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$11.0M -156.1% | -$4.3M -186.5% | $5.0M +362.2% | $1.1M -82.5% | $6.1M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$12.1M -5.7% | -$11.4M +38.1% | -$18.5M -281.0% | -$4.8M +83.3% | -$29.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -12.6% +1.3pp | -13.9% +10.5pp | -24.4% -18.0pp | -6.4% +18.0pp | -24.4% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $49.0K +228.9% | -$38.0K -258.3% | $24.0K +100.5% | -$5.2M +74.0% | -$20.1M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$12.1M +39.9% | -$20.2M +69.6% | -$66.4M +52.5% | -$139.8M -1469.4% | -$8.9M | $4.9B | $4.8B | $4.7B |
| Net Margin | -12.6% +11.9pp | -24.5% +63.0pp | -87.6% +95.8pp | -183.4% -175.9pp | -7.5% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 +43.2% | -$0 +71.1% | -$2 +53.8% | -$3 -1330.4% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 +43.2% | -$0 +71.1% | -$2 +53.8% | -$3 -1330.4% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $47.8M +3.7% | $46.1M +5.4% | $43.7M +2.9% | $42.5M +10.3% | $38.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $48.6M +5.6% | $46.1M +5.4% | $43.7M +2.9% | $42.5M +10.3% | $38.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Establishment Labs Holdings Inc.
NASDAQ:ESTA
$2.51B
Neogen Corporation
NASDAQ:NEOG
$1.98B
Pulse Biosciences, Inc.
NASDAQ:PLSE
$1.81B
NovoCure Limited
NASDAQ:NVCR
$1.71B
Harrow Health, Inc.
NASDAQ:HROW
$1.56B
STAAR Surgical Company
NASDAQ:STAA
$1.43B
AtriCure, Inc.
NASDAQ:ATRC
$1.42B
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
$1.11B
Azenta, Inc.
NASDAQ:AZTA
$1.05B
Phreesia, Inc.
NYSE:PHR
$581.65M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does BLFS generate?
BioLife Solutions, Inc. (BLFS) reported $96.21M of revenue in fiscal 2025.
Is BLFS profitable?
BioLife Solutions, Inc. (BLFS) reported -$12,130,000.00 of net income, with a net margin of -12.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.